{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=6", "query": { "condition": "Neuroendocrine Cancer", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 2740, "total_pages": 274, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neuroendocrine+Cancer&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T09:38:59.127Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05619744", "title": "A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Small Cell Lung Cancer", "Neuroendocrine Carcinoma" ], "interventions": [ { "name": "RO7616789", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2023-01-23", "completion_date": "2025-03-04", "has_results": false, "last_update_posted_date": "2025-03-10", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 10, "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Detroit, Michigan + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05619744" }, { "nct_id": "NCT01502293", "title": "Trial of pIL-12 Electroporation Malignant Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Tavokinogene Telseplasmid (tavo)", "type": "BIOLOGICAL" }, { "name": "OncoSec Medical System (OMS)", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "OncoSec Medical Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2012-02-14", "completion_date": "2016-03-21", "has_results": true, "last_update_posted_date": "2023-05-15", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 6, "location_summary": "San Francisco, California • Santa Monica, California • Denver, Colorado + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lakeland", "state": "Florida" }, { "city": "Bethlehem", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01502293" }, { "nct_id": "NCT02030184", "title": "Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer (SCLC)", "Neuroendocrine (NE) Tumors", "Large Cell Neuroendocrine (NE) Tumors" ], "interventions": [ { "name": "Rhenium Re 188-P2045", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-06", "completion_date": "2021-06", "has_results": false, "last_update_posted_date": "2019-10-17", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02030184" }, { "nct_id": "NCT03428581", "title": "Preventing Lymphedema in Axillary Lymph Node Dissection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lymphedema", "Breast Cancer", "Melanoma" ], "interventions": [ { "name": "ALND with ARM +/- LVB", "type": "PROCEDURE" }, { "name": "ALND", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 264, "start_date": "2018-04-10", "completion_date": "2025-07-11", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03428581" }, { "nct_id": "NCT00001898", "title": "Microarray Analysis for Human Genetic Disease", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Neoplasm", "Hereditary Neoplastic Syndrome", "Melanoma", "Ovarian Neoplasm" ], "interventions": [], "intervention_types": [], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1500, "start_date": "1999-06-29", "completion_date": "2008-05-20", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 5, "location_summary": "Tucson, Arizona • Baltimore, Maryland • Ann Arbor, Michigan + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001898" }, { "nct_id": "NCT02557321", "title": "PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "PV-10", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Provectus Biopharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2015-10", "completion_date": "2025-04", "has_results": false, "last_update_posted_date": "2023-11-21", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 5, "location_summary": "Tampa, Florida • Lebanon, New Hampshire • Portland, Oregon + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Portland", "state": "Oregon" }, { "city": "Easton", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02557321" }, { "nct_id": "NCT01316692", "title": "Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IIIc Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "laboratory biomarker identification and analysis", "type": "OTHER" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "immunohistochemistry/tissue microarrays", "type": "OTHER" }, { "name": "TdT-mediated dUTP nick end labeling assay", "type": "GENETIC" }, { "name": "mass spectrometry", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "GENETIC" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2011-10", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01316692" }, { "nct_id": "NCT03635632", "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Neuroblastoma", "Refractory Neuroblastoma", "Relapsed Osteosarcoma", "Relapsed Ewing Sarcoma", "Relapsed Rhabdomyosarcoma", "Uveal Melanoma", "Phyllodes Breast Tumor" ], "interventions": [ { "name": "C7R-GD2.CART cells", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "74 Years", "sex": "ALL", "summary": "1 Year to 74 Years" }, "enrollment_count": 94, "start_date": "2019-04-23", "completion_date": "2038-05-16", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03635632" }, { "nct_id": "NCT02009384", "title": "Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Louisville", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2012-01", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 1, "location_summary": "Louisville, Kentucky", "locations": [ { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02009384" }, { "nct_id": "NCT06880549", "title": "A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "mRNA-4106", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "mRNA-4200", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2025-03-25", "completion_date": "2027-08-03", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T09:38:59.127Z", "location_count": 4, "location_summary": "Los Angeles, California • Grand Rapids, Michigan • San Antonio, Texas + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06880549" } ] }